Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
World Neurosurg. 2021 May;149:e63-e70. doi: 10.1016/j.wneu.2021.02.090. Epub 2021 Feb 26.
Carbamazepine (CBZ) is the first-line therapy for trigeminal neuralgia (TN), and microvascular decompression (MVD) is considered to be an effective surgical treatment for TN. However, the effect of preoperative CBZ treatment on MVD outcome is not clear.
From 2013 to 2019, 63 patients with classical TN underwent MVD at the First Affiliated Hospital of Zhengzhou University, China. Data were collected through telephone follow-up and electronic medical records in April 2020. Short-term surgical outcome and long-term follow-up data were estimated by univariate and multivariate analysis.
Multivariate analysis indicated that preoperative CBZ treatment was not a significant predictor for short-term outcomes of MVD (P > 0.05). Multivariate analysis for the long-term outcome of MVD indicated that preoperative CBZ treatment could predict postoperative recurrence of TN (P < 0.05).
For patients with classical TN, a longer preoperative medication history of CBZ treatment had no significant effect on short-term outcome of MVD, but CBZ treatment was associated with a poor long-term outcome following MVD.
卡马西平（CBZ）是治疗三叉神经痛（TN）的一线药物，微血管减压术（MVD）被认为是治疗 TN 的有效手术方法。然而，术前 CBZ 治疗对 MVD 结果的影响尚不清楚。
2013 年至 2019 年，中国郑州大学第一附属医院对 63 例经典型 TN 患者行 MVD 治疗。通过 2020 年 4 月的电话随访和电子病历收集数据。通过单变量和多变量分析评估短期手术结果和长期随访数据。
多变量分析表明，术前 CBZ 治疗不是 MVD 短期结果的显著预测因素（P>0.05）。MVD 长期结果的多变量分析表明，术前 CBZ 治疗可预测 TN 的术后复发（P<0.05）。
对于经典型 TN 患者，较长的术前 CBZ 治疗药物史对 MVD 的短期结果没有显著影响，但 CBZ 治疗与 MVD 后不良的长期结果相关。
